Abstract:Objective To study the changes and significance of CD4+ CD25+ regulatory T cells (Treg) and serum interleukin (IL)-10 in myelodysplastic syndrome (MDS) patients.Methods From October 2010 to December 2012,a total of 23 cases of MDS patients who were newly diagnosed in Department of Hematology,Xinghua People s Hospital of Jiangsu Province were included into this study,as study group (n=23).And they were divided into four subgroups according to the International Prognostic Scoring System (IPSS),high risk group (n=5),medium risk-Ⅰ group (n=11),medium risk-Ⅱ group (n=4) and low risk group (n=3).During the same period and in the same hospital,a total of 10 cases of non-malignant immune hematologic diseases patients,such as iron deficiency anemia and megaloblastic anemia were chose as control group (n=10).All patients in study group and control group,their CD4+ CD25+Treg and serum IL-10 were detected by flow cytometry and enzyme linked immunosorbent assay (ELISA),respectively,and then they were analyzed by statistical methods.There were no significant differences of patients' general clinical features between two groups and subgroup,respectively (P＞0.05).The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Xinghua People's Hospital of Jiangsu Province.Informed consent was obtained from all patients.Results ① The percentage of CD4+ CD25+ Treg and serum IL-10 expression level in study group were (6.89± 1.28)％ and (7.02±1.83) μg/L,respectively,which were significantly higher than those of control group (2.72 ± 0.46)％ and (3.72±1.76) μg/L,and the differences were statistically significant (t=5.263,3.824;P＜0.05).② In study group,the percentage of CD4+ CD25+ Treg and serum IL-10 expression level of four subgroups compared as a whole,the differences were statistically significant (F=10.464,9.898;P＜0.05).Among the four subgroups,CD4+ CD25+ Treg percentage and serum IL-10 expression level compared between the low-risk group and moderate Ⅰ group,between moderate Ⅱ group and high-risk group,there were no statistically significant differences (P＞0.05).But the CD4+ CD25+ Treg percentage and IL-10 expression level compared between low-risk group and moderate Ⅱ group,low-risk group and high-risk group,moderate Ⅰ group and moderate Ⅱ group,and between moderate Ⅰ group and high-risk group,the differences were all statistically significant (P＜ 0.05).③ There were positive correlations between peripheral blood CD4+ CD25+ Treg percentage and serum IL-10 expression level of MDS patients (r=0.326,P=0.326).Conclusions The number of CD4+ CD25+ Treg and (or) its function imbalance plays an important role in the occurrence and development of MDS,and the percentage of CD4+ CD25+ Treg and serum IL-10 expression levels increase along with the growth of prognostic risk,suggesting that abnormal immunity is a contributing factor to the occurrence and development of MDS.So the CD4+ CD25+ Treg might be a new target for targeted immune therapy of MDS.

Effect of IL-15 on the Proliferation of CD34+ Cells in Patients with MDS

Effect of IL-15 on the Proliferation, Differentiation and Antiapoptosis of CD34 + Cells in Patients with MDS

The Effect of Rhil-15 on the Antitumor Activity of Cord Blood and Peripheral Blood Mononuclear Cell

The Efficacy of IL-15 on the Antitumor Activity of Cord Blood Adononuclear Cell

Depleting Autologous Activated CD4 T Lymphocytes Improves in Vitro Generation of Colony-Forming Units in Progenitor Culture in Myelodysplastic Syndrome

Changes and significance of CD4+ CD25+ regulatory T cells and serum interleukin-10 in myelodysplastic syndrome patients

Study on the Effect of IL-12 and IL-15 on the Proliferation of CIK Cells from of Peripheral Blood and the Activity of Killing SMMC-7721 Hepatoma Cell Line in Vitro

Clinical study of the number of circulating CD34~+ cells in the peripheral blood from patients with myelodysplastic syndromes

Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome

Study on Activation of NK Cells by IL- 15 and GM-CSF

CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression

[Expression of Insulin-like Growth Factor Recepter Type I in CD34+ Cells of Patients with Myelodysplastic Syndromes].

Biological implications of circulating CD34(+) cells in myelodysplastic syndromes

Influence of Human Bone Marrow Mesenchymal Stem Cells on Proliferation of Chronic Myeloid Leukemia Cells.

Effect of interleukin (IL)-12 and IL-15 on apoptosis and proliferation of umbilical cord blood mononuclear cells

The Effect of Hematopoietic Stem Cell Transplantation on Myelodysplastic Syndrome

Analysis of Proliferation Characters of Bone Marrow Mesenchymal Stem Cells Derived from Patients with Myelodysplastic Syndrome

Experimental and Clinical Characteristics in Myelodysplastic Syndrome Patients with or Without Hla-Dr15 Allele

Clinical analysis for thirty patients with myelodysplastic syndromes

[IL-15 Enhance the Therapeutic Effects of Whole Cell Vaccine in Mouse CT26 Colon Carcinoma Model].